These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28830481)

  • 1. Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016.
    Gagnon MA; Volesky KD
    Global Health; 2017 Aug; 13(1):62. PubMed ID: 28830481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
    Wouters OJ; Kanavos PG; McKEE M
    Milbank Q; 2017 Sep; 95(3):554-601. PubMed ID: 28895227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blizzard deals. In a sure sign of a robust industry, companies recently have gotten in the spirit to merge and acquire.
    Galloro V
    Mod Healthc; 2004 Dec; 34(50):6-7, 1. PubMed ID: 15631144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life sciences licensing deals in the second quarter of 2018: updates and trends.
    D'Souza P
    Drugs Today (Barc); 2018 Oct; 54(10):629-637. PubMed ID: 30398483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.
    Dierks RML; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):147-160. PubMed ID: 29243501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mergers + acquisitions.
    Hoppszallern S
    Hosp Health Netw; 2002 May; 76(5):51, 53-6, 2. PubMed ID: 12035575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions.
    Barbieri E; Huang M; Pi S; Tassinari M
    Int J Environ Res Public Health; 2017 Oct; 14(10):. PubMed ID: 28981463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. By the numbers. Largest healthcare services mergers/acquisitions announced in 2007. U.S. deals ranked by deal's price.
    Mod Healthc; 2008 Jan; 38(3):32. PubMed ID: 18318390
    [No Abstract]   [Full Text] [Related]  

  • 14. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merger and acquisition medicine.
    Powell GS
    Occup Med; 1997; 12(1):163-8. PubMed ID: 9153061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Let's make a deal. Healthcare mergers, acquisitions take place at dizzying pace.
    Lutz S
    Mod Healthc; 1994 Dec 19-26; 24(51):47-50, 52. PubMed ID: 10138912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HMO mergers and acquisitions on financial performance.
    Weech-Maldonado R
    J Health Care Finance; 2002; 29(2):64-77. PubMed ID: 12462660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-cost generic drugs--implications for patients and policymakers.
    Alpern JD; Stauffer WM; Kesselheim AS
    N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.